Acute Decompensated Heart Failure Update
John R. Teerlink, Khalid Alburikan, Marco Metra and Jo E. Rodgers
Affiliation: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7569, Chapel Hill, NC 27599, USA.
Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial
mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more
than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will
rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result
of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been
conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address
the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal
management of ADHF.
Keywords: Acute decompensated heart failure, diuretics, inotropes, vasodilators.
Rights & PermissionsPrintExport